VRTX
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Vertex reports positive Phase 2b AMPLIFIED results for inaxaplin in additional APOL1-mediated kidney disease populations and completes enrollment in Phase 2/3 AMPLITUDESep 22, 2026
- Vertex collaborates with AbCellera to discover multispecific T-cell engagers for autoimmune diseasesJul 29, 2026
- Vertex received FDA approval to expand CASGEVY use to patients aged 2 years and olderJul 2, 2026
- Vertex received FDA approval for label expansions of ALYFTREK and TRIKAFTA to broaden access for cystic fibrosis patientsApr 1, 2026
- Vertex reported positive week-36 interim results meeting primary and secondary endpoints in the Phase 3 RAINIER trial of povetacicept for IgA nephropathyMar 10, 2026